CAMBRIDGE, Mass. (Nov 10, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) will present data from its ongoing nonclinical study of Neuro-Spinal Scaffold™implantation at Neuroscience 2016, the Society for Neuroscience 46th annual conference November 12-16 in San Diego. The company’s oral presentation entitled “The Neuro-Spinal Scaffold promotes tissue remodeling, axonal sprouting, and Schwann cell myelination following acute spinal cord contusion injury in rats” will be presented by Simon Moore, Ph.D., Director of Research on Monday, November 14 at 2:15 PM (PST) during the Brain and Spinal Cord Injury nanosymposium.
“I look forward to sharing these latest Neuro-Spinal Scaffold nonclinical findings with the neuroscience community,” Dr. Moore said. “In the data to be presented at Neuroscience 2016, we examine findings regarding spinal cord preservation, neural regeneration and remyelination in animal models of spinal cord injury, contributing to the growing body of spinal cord injury research.”
This is the tenth scientific or medical meeting in which InVivo Therapeutics or its collaborators have presented data from the Neuro-Spinal Scaffold program this year.
“We continue to present exciting results from our research in hopes of redefining the life of the spinal cord injury patient,” said Mark Perrin, CEO of InVivo Therapeutics. “These data illustrate the potential mechanisms of action of the Neuro-Spinal Scaffold, which we are investigating clinically as a treatment option for this underserved patient community.”
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.